Navigation Links
The Rudd Report, Dated April 18, 2008, Updates AMDL's Recent Achievements
Date:4/25/2008

TUSTIN, Calif., April 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), an international biopharma company with development and manufacture of proprietary pharmaceutical and diagnostic products in China, announced today that a 4th Quarter Update and Year End Report on AMDL has been posted by analyst Lauren Rudd at (http://www.RuddReport.com). It includes a 12 month target price of $23 and a Buy Recommendation.

The Report highlights AMDL's recent and anticipated company goals and objectives in regards to DR-70(TM), Human Papilloma Virus (HPV), Jade Pharmaceutical Inc. 2008 business expansion and JPGreen Health & Beauty Clinics. It also covers various Peer Group Comparison & Valuation Analysis and their views and opinions on financial performance for FY2008.

The 21-page report goes into significant detail about AMDL's products, particularly AMDL's recent announcement in April 2008 that it has entered into an exclusive sublicense agreement for a diagnostic product for in-vitro genotype testing in women with Human Papilloma Virus (HPV), a potential billion dollar market.

"AMDL has had another profitable quarter, making it two in a row, a trend we feel goes a long way towards reaffirming our current projections that by the end of 2008, revenues from Jade alone will reach or exceed $38 million," Mr. Rudd writes.

About Jade Pharmaceutical Inc.: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injectable fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Disclaimer by Rudd

This disclaimer is an integral part of Rudd's service. Please read it before investing in any security on which we report.

Opinions are solely those of the staff of The Rudd Report and are subject to change without notice. Our reports are for information only and we do not offer securities or solicit the offer of securities of any company. Our reports are to inform the public and not to promote any company or its securities.

We do not inform any company in advance of the nature or conclusions of our reports nor can a company change what we write.

In the case of AMDL we received a fee for coverage of the current quarter in the amount of $6,000.

Our reports contain factual statements and opinions. We derive these factual statements from sources that we believe are accurate. However, we do not represent that the facts presented are accurate or complete. Furthermore, the information contained in this report may become inaccurate because of the passage of time and should therefore be read for historical information only.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

Voice Mail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gateway Health Plan Ranked Again Among Americas Best Health Plans According to U.S. News & World Report, NCQA
2. U.S.News & World Report, NCQA Release Annual Rankings for Americas Best Health Plans
3. Academy of General Dentistry Releases Updated Employment Statistical Map
4. American Media, Inc. Provides Lenders With Updated Information
5. Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill-Rom and Batesville Casket
6. Health groups issue updated colorectal cancer screening guidelines
7. UPDATED: Catholic Healthcare West and SEIU Begin Negotiations for 15,000 Hospital Workers
8. Alliance for Quality Nursing Home Care Praises CMS Release of Updated Special Focus Facilities (SFF) List
9. Consumer Group Finds Use of Outdated Data and Other Major Flaws in Economists Defense of Mandatory Purchase of Private Health Insurance
10. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
11. CAHI Releases Updated Health Insurance Mandates in the States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: